SEARCH RESULT

Total Matching Records found : 2073

Drugs, Ranbaxy and lies

-The Hindu Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed...

More »

Government's manufacturing zones land in trouble -Yogima Seth Sharma & Dilasha Seth

-The Economic Times NEW DELHI: The government's ambitious manufacturing thrust has run into trouble even before it could take off with many states expressing difficulty in acquiring the vast tracts of land needed to set up dedicated zones. Five states have written to the Department of Industrial Policy and Promotion, requesting it to consider revising the minimum land requirement (from existing 5,000 hectare) for developing National Manufacturing Investment Zones (NMIZs). These include Assam,...

More »

Dinesh Thakur, an ex-Ranbaxy employee who blew the whistle on the company, interviewed by The Economic Times

-The Economic Times Indian pharmaceutical company Ranbaxy recently paid $500 million to the US government to settle civil and criminal charges for making fraudulent statements to the US FDA and selling adulterated drugs in the US. Dinesh Thakur, an ex-Ranbaxy employee who blew the whistle on the company, talks to ET about the five-year long investigation and the future of generic drug companies in the US. Edited Excerpts: * You think you...

More »

USFDA scrutiny: Will pharma majors like Ranbaxy, Wockhardt be affected in long-term? -G Seetharaman

-The Economic Times Japanese companies do not mind erring on the side of caution. They are known to think longer and harder than their counterparts in other countries about big decisions, especially when it comes to entering a new market or acquiring a foreign company. But Japan's third biggest drugmaker Daiichi Sankyo would now wish it had spent more time doing due diligence on Ranbaxy Labs, in which it bought a...

More »

Mandatory CSR in India: A Bad Proposal-Aneel Karnani

-Stanford Social Innovation Review Looked at from the perspective of the political right, and the left, and the center, the proposed law making CSR mandatory is a really bad idea. Companies all over the world are under increasing pressure to demonstrate that they are responsible citizens, with about 70 percent of large companies in Europe and the Americas reporting on their corporate social responsibility (CSR) initiatives. Despite this, the very concept...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close